Hodgkin's disease
Adult: Monotherapy: Initially, 50 mg/day, increased by 50 mg daily to 250-300 mg daily in divided doses. Continue doses until max response is achieved or appearance of signs of toxicity. Maintenance: 50-150 mg/day or 1-2 mg/kg daily until a cumulative dose of at least 6 g. Combination Therapy: 100 mg/m2 on days 1-14 of each 4- or 6-wk cycle.
Child: Initially, 50 mg/m2 daily, up to 100 mg/m2 adjust according to response.
Pregnancy. Lactation. Myelosuppression. Severe hepatic and renal impairment.
Warnings / Precautions
May increase blood glucose in diabetics. Monitor peripheral blood counts regularly. Monitor hepatic and renal function wkly. Pheochromocytoma, epilepsy, CV or cerebrovascular disease., hepatic or renal impairment Discontinue use if hypersensitivity occurs.
Adverse Reactions
GI disturbances, anorexia, nausea and vomiting; bone marrow depression; leukopenia and thrombocytopaenia; anaemia, haemolysis and bleeding tendencies; neurotoxicity, lethargy, ataxia and sleep disorders. Fever, myalgia, pulmonary fibrosis or pneumonitis, haematuria, urinary frequency, skin reactions, tachycardia, orthostatic hypotension, ocular defects, infertility and hepatic impairment.
Drug Interactions
Increased risk of hypersensitivity reactions when used with enzyme-inducing antiepileptics. Potentiation of sedative effects with CNS depressants. Increased risk of agranulocytosis with clozapine. Disulfiram-like reaction with alcohol. May enhance the anithypertensive effects of antihypertensive agents.
See Below for More procarbazine Drug Interactions
Mechanism of Actions
Procabazine, an alkylating agent, damages DNA, inhibits DNA, RNA and protein synthesis. It is able to block the MAO action in the CNS. It is not cross-resistant with other alkylating agents and is S-phase specific.
Absorption: Readily absorbed from the GI tract.
Distribution: Crosses the blood-brain barrier and diffuses into the CSF.
Metabolism: Rapidly metabolised mainly in the liver and kidneys.
Excretion: About 5% excreted unchanged in urine.
Storage Conditions
Oral: Protect from light.
ATC Classification
L01XB01 - procarbazine ; Belongs to the class of methylhydrazines . Used in the treatment of cancer.
Oral: Protect from light.
Available As
  • Procarbazine 20 mg
  • Procarbazine 50 mg
  • Subscribe for latest updates

    Subscribe to our e-mail newsletter to receive updates.

    No comments yet.

    Post Review about Procarbazine

    Procarbazine Containing Brands

    We are Developing Our database, More results coming soon.

    Procarbazine is used in following diseases

    We are Developing Our database, More results coming soon.

    Drug - Drug Interactions of Procarbazine

    We are Developing Our database, More results coming soon.